Eptifibatide

In the US, Eptifibatide (eptifibatide systemic) is a member of the drug class glycoprotein platelet inhibitors and is used to treat Acute Coronary Syndrome, Angina, Heart Attack and Percutaneous Coronary Intervention.

US matches:

• Eptifibatide

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

B01AC16

CAS registry number (Chemical Abstracts Service)

0148031-34-9

Chemical Formula

C35-H49-N11-O9-S2

Molecular Weight

833

Therapeutic Category

Antiplatelet agent, glycoprotein IIb/IIIa-receptor antagonist

Chemical Name

Cyclo(S-S)-mercaptopropionyl-(L) homoarginyl-glycyl-(L) aspartyl-(L) tryptophanyl-(L) prolyl-(L) cysteinamide

Foreign Names

• Eptifibatidum (Latin)
• Eptifibatid (German)
• Eptifibatide (French)
• Eptifibatida (Spanish)

Generic Names

• Eptifibatide (OS: DCF, BAN)
• C 6822 (IS)
• Intrifiban (IS)
• SB 1 (IS)
• SCH 60936 (IS)

Brand Names

• Integrilin
  Glaxo Group, Austria; Glaxo Group, Bulgaria; Glaxo Group, Iceland; Glaxo Group, Luxembourg; Glaxo SmithKline, Spain; GlaxoSmithKline, Belgium; GlaxoSmithKline, Switzerland; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Finland; GlaxoSmithKline, France; GlaxoSmithKline, United Kingdom; GlaxoSmithKline, Greece; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Hungary; GlaxoSmithKline, Italy; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Norway; GlaxoSmithKline, Poland; GlaxoSmithKline, Portugal; GlaxoSmithKline, Russian Federation; GlaxoSmithKline, Slovakia; Millennium, United States; Schering, United States; Schering-Plough, Argentina; Schering-Plough, Australia; Schering-Plough, Bulgaria; Schering-Plough, Bahrain; Schering-Plough, Canada; Schering-Plough, Hong Kong; Schering-Plough, Indonesia; Schering-Plough, Ireland; Schering-Plough, Israel; Schering-Plough, New Zealand; Schering-Plough, Philippines; Schering-Plough, Romania; Schering-Plough, Singapore; Schering-Plough, Slovenia; Schering-Plough, Thailand; Schering-Plough, South Africa



• INTEGRILIN
  GlaxoSmithKline, Sweden



• Intergrilin
  Schering-Plough, South Africa

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.